secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001213900-21-055781
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD
--------------------------------------------------------------------------------

- Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.
- Cash and marketable securities $73.8M as of Sep 30, 2021, up from $19.2M at Dec 31, 2020.
- RADR platform surpassed 10 billion curated oncology data points, up from 4.6B in earlier 2021.
- LP-184 received Orphan Drug Designation from FDA for pancreatic cancer and glioblastoma.
- Announced strategic collaborations with Deep Lens and Code Ocean; planning Phase 2 trial for LP-300.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/0001213900-21-055781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/ea149696-8k_lantern.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-055781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer